Human HDAC6 with H611A mutation (GenBank Accession No. NM_006044), full length with Nterminal GST tag, MW= 161 kDa, expressed in a baculovirus expression system.

Q9UBN7

histone deacetylase 6, HDAC6

0.83 pmole/min/µg

Assay Conditions: 25 mM Tris/HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, and 0.1 mg/ml BSA, 20 µM BPS HDAC substrate 3 (Catalog #50037), and HDAC6 H611A (15 – 1000 ng). Incubation condition: 30 min at 37ºC followed by developing for 15 min at room temperature.

40 mM Tris-HCl, pH 8.0, 110 mM NaCl, 2.2 mM KCl, 0.04% Tween-20 and 20% Glycerol.

Protein was purified by affinity chromatography and gel filtration.

Aqueous buffer solution

At least 6 months at –80°C.

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Li S. et al., Neurology. 2010; 41(2): 112-6.

2. Strausberg, R.L. et al., Proc. Natl. Acad. Sci. U.S.A. 2002; 99(26): 16899-16903.

Application References:
1. Kinetic method for the large-scale analysis of the binding mechanism of histone deacetylase inhibitors (2014)
2. Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform (2013)
3. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp (2013)
4. Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors (2013)

Avoid freeze/thaw cycles. Storing diluted enzyme is not recommended, if necessary, use carrier protein (BSA 0.1 – 0.5%).

Deacetylase

Recombinant Protein